Indication · Gaucher's Disease Type III

Gaucher's Disease Type III FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 Gaucher's Disease Type III drug. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
Cerezyme (imiglucerase)SNYbiologic—

Upcoming catalysts

DateDrugCompanyEventIndicationStatusSource
Jan to Apr 2030Quarter disclosedCerezyme (imiglucerase)SNYTopline readoutGaucher's Disease Type IIIScheduledClinicalTrials.gov
January 2030Month disclosedCerezyme (imiglucerase)SNYPrimary completionGaucher's Disease Type IIIScheduledClinicalTrials.gov

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
October 2, 2025Cerezyme (imiglucerase)SNYPrimary completionGaucher's Disease Type IIICompletedClinicalTrials.gov

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 3.

Questions

What Gaucher's Disease Type III drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.